Associations between β-Blocker Therapy at Discharge and Long-Term Follow-Up Outcomes in Patients with Unstable Angina Pectoris

Table 4

Secondary endpoints in patients with UAP in the β-blocker and no β-blocker groups.

	Before PS match			After PS match
	β-Blocker (-) N = 1801	β-Blocker (+) N = 3790	value	β-Blocker (-) N = 1786	β-Blocker (+) N = 1786	value
Event
All-cause death or heart failure
No. of patients	68	214		67	99
Event rate (%)	3.8	5.6	0.003	3.8	5.5	0.011
Unadjusted HR (95% CI)	1.00	1.41 (1.07, 1.85)	0.013	1.00	1.40 (1.03, 1.91)	0.033
Adjusted HR (95% CI)	1.00	1.16 (0.88,1.53)	0.296	1.00	1.20 (0.88, 1.65)	0.256
All-cause death, heart failure, or nonfatal MI
No. of patients	94	272		93	128
Event rate (%)	5.2	7.2	0.006	5.2	7.2	0.015
Unadjusted HR (95% CI)	1.00	1.30 (1.03, 1.65)	0.027	1.00	1.31 (1.01, 1.71)	0.046
Adjusted HR (95% CI)	1.00	1.08 (0.85, 1.38)	0.520	1.00	1.17 (0.89,1.53)	0.267
All-cause death, heart failure, nonfatal MI, or nonfatal stroke
No. of patients	108	305		107	141
Event rate (%)	6.0	8.0	0.006	6.0	7.9	0.025
Unadjusted HR (95% CI)	1.00	1.27 (1.02, 1.58)	0.035	1.00	1.25 (0.97, 1.61)	0.082
Adjusted HR (95% CI)	1.00	1.04 (0.83, 1.31)	0.712	1.00	1.11 (0.86, 1.44)	0.410

Data are presented as number or HR (95% CI). MI, myocardial infarction.